MFDS PMS exemptions: two groups of overseas-use evidence
Article 9 of Korea’s post-market investigation provisions defines overseas-use experience and requires two evidence groups. Clinical or post-market research is one group; overseas authorization, sales, use and adverse-event analysis form the other. Foreign marketing alone does not establish an exemption.